AML With Myelodysplasia-related Features - 27 Studies Found Withdrawn : Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies : Accelerated Phase Chronic Myelogenous Leukemia Acute Myeloid Leukemia : 2012-07-20 : Drug: cyclophosphamide Given I Active, not recruiting : Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders : Accelerated Phase Chronic Myelogenous Leukemia Acute Myeloid Leukemia : 2009-03-04 : Drug: fludarabine phosphate Gi Completed : A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies : Accelerated Phase Chronic Myelogenous Leukemia Acute Myeloid Leukemia : 2006-06-22 : Drug: cyclophosphamide Given I Terminated : Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant : Accelerated Phase Chronic Myelogenous Leukemia Acute Myeloid Leukemia : 2003-01-24 : Biological: therapeutic allogeneic lymphocytes Completed : Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy : Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk : 2010-11-04 : Procedure: standard follow-up care Active, not recruiting : Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies : Leukemia Myelodysplastic Syndromes : 2007-10-13 : Drug: fludarabine phosphate 25 Completed : Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia : Leukemia Myelodysplastic Syndromes : 2009-02-13 : Other: medical chart review Other: questio <<< Previous
